nach oben

Diabetologia

Erschienen in:

02.01.2020 | Review

The changing face of paediatric diabetes

verfasst von: Amy S. Shah, Kristen J. Nadeau

Erschienen in: Diabetologia | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this review is to provide an update on the changing face of paediatric type 1 diabetes and type 2 diabetes. Paediatric diabetes is on the rise, with extensive research dedicated to understanding its pathophysiology, comorbidities and complications. As obesity continues to increase among all youth, differentiating between type 1 diabetes and type 2 diabetes has become increasingly difficult but remains important for optimising treatment, anticipating complications and predicting disease risk. Novel treatments are emerging, with the ultimate goal being to achieve glycaemic control, limit weight gain, improve quality of life and reduce comorbidities. In this review, we focus on updates regarding the epidemiology, clinical presentation, comorbidities and complications of paediatric type 1 diabetes and type 2 diabetes and conclude with current and emerging treatments.

Nur mit Berechtigung zugänglich

Jahromi MM, Eisenbarth GS (2007) Cellular and molecular pathogenesis of type 1A diabetes. Cell Mol Life Sci 64(7-8):865–872. https://doi.org/10.1007/s00018-007-6469-4 CrossRefPubMed

Defronzo RA (2009) Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58(4):773–795. https://doi.org/10.2337/db09-9028 CrossRefPubMedPubMedCentral

Copeland KC, Zeitler P, Geffner M et al (2011) Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab 96:159–167CrossRefPubMed

Avery AR, Duncan GE (2019) Heritability of type 2 diabetes in the Washington State Twin Registry. Twin Res Hum Genet 22(2):95–98. https://doi.org/10.1017/thg.2019.11 CrossRefPubMedPubMedCentral

Dabelea D, Mayer-Davis EJ, Saydah S et al (2014) Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 311:1778–1786CrossRefPubMedPubMedCentral

Stanescu DE, Lord K, Lipman TH (2012) The epidemiology of type 1 diabetes in children. Endocrinol Metab Clin N Am 41:679–694CrossRef

Harjutsalo V, Sund R, Knip M, Groop PH (2013) Incidence of type 1 diabetes in Finland. JAMA 310:427–428CrossRefPubMed

Harjutsalo V, Sjoberg L, Tuomilehto J (2008) Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 371:1777–1782CrossRefPubMed

Silink M (2002) Childhood diabetes: a global perspective. Horm Res 57(Suppl 1):1–5PubMed

10.

Mayer-Davis EJ, Lawrence JM, Dabelea D et al (2017) Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. N Engl J Med 376:1419–1429CrossRefPubMedPubMedCentral

11.

Newhook LA, Curtis J, Hagerty D et al (2004) High incidence of childhood type 1 diabetes in the Avalon Peninsula, Newfoundland, Canada. Diabetes Care 27(4):885–888. https://doi.org/10.2337/diacare.27.4.885 CrossRefPubMed

12.

Ehtisham S, Barrett TG, Shaw NJ (2000) Type 2 diabetes mellitus in UK children – an emerging problem. Diabet Med 17(12):867–871. https://doi.org/10.1046/j.1464-5491.2000.00409.x CrossRefPubMed

13.

Amutha A, Datta M, Unnikrishnan IR et al (2011) Clinical profile of diabetes in the young seen between 1992 and 2009 at a specialist diabetes centre in south India. Prim Care Diabetes 5(4):223–229. https://doi.org/10.1016/j.pcd.2011.04.003 CrossRefPubMed

14.

Urakami T, Suzuki J, Mugishima H et al (2012) Screening and treatment of childhood type 1 and type 2 diabetes mellitus in Japan. Pediatr Endocrinol Rev 10(Suppl 1):51–61PubMed

15.

Dabelea D, Pihoker C, Talton JW et al (2011) Etiological approach to characterization of diabetes type: the SEARCH for Diabetes in Youth Study. Diabetes Care 34(7):1628–1633. https://doi.org/10.2337/dc10-2324 CrossRefPubMedPubMedCentral

16.

Quinn M, Fleischman A, Rosner B, Nigrin DJ, Wolfsdorf JI (2006) Characteristics at diagnosis of type 1 diabetes in children younger than 6 years. J Pediatr 148:366–371CrossRefPubMed

17.

Dabelea D, Rewers A, Stafford JM et al (2014) Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study. Pediatrics 133(4):e938–e945. https://doi.org/10.1542/peds.2013-2795 CrossRefPubMedPubMedCentral

18.

Klingensmith GJ, Connor CG, Ruedy KJ et al (2016) Presentation of youth with type 2 diabetes in the Pediatric Diabetes Consortium. Pediatr Diabetes 17(4):266–273. https://doi.org/10.1111/pedi.12281 CrossRefPubMed

19.

Robinson ME, Li P, Rahme E, Simard M, Larocque I, Nakhla MM (2019) Increasing prevalence of diabetic ketoacidosis at diabetes diagnosis among children in Quebec: a population-based retrospective cohort study. CMAJ Open 7(2):E300–E305. https://doi.org/10.9778/cmajo.20190047 CrossRefPubMedPubMedCentral

20.

Dabelea D, Bell RA, D’Agostino RB Jr et al (2007) Incidence of diabetes in youth in the United States. JAMA 297(24):2716–2724. https://doi.org/10.1001/jama.297.24.2716 CrossRefPubMed

21.

Minges KE, Whittemore R, Grey M (2013) Overweight and obesity in youth with type 1 diabetes. Annu Rev Nurs Res 31:47–69. https://doi.org/10.1891/0739-6686.31.47 CrossRefPubMedPubMedCentral

22.

DuBose SN, Hermann JM, Tamborlane WV et al (2015) Obesity in youth with type 1 diabetes in Germany, Austria, and the United States. J Pediatr 167:627–632.e621-e624CrossRefPubMed

23.

Bjornstad P, Maahs DM, Duca LM et al (2016) Estimated insulin sensitivity predicts incident micro- and macrovascular complications in adults with type 1 diabetes over 6 years: the coronary artery calcification in type 1 diabetes study. J Diabetes Complicat 30:586–590CrossRef

24.

Specht BJ, Wadwa RP, Snell-Bergeon JK, Nadeau KJ, Bishop FK, Maahs DM (2013) Estimated insulin sensitivity and cardiovascular disease risk factors in adolescents with and without type 1 diabetes. J Pediatr 162:297–301CrossRefPubMed

25.

Cree-Green M, Wiromrat P, Stuppy J et al (2019) Youth with Type 2 diabetes have hepatic, peripheral and adipose insulin resistance. AJP Endo 316:E186–E195

26.

Zeitler P, Arslanian S, Fu J et al (2018) ISPAD Clinical Practice Consensus Guidelines 2018: type 2 diabetes mellitus in youth. Pediatr Diabetes 19(Suppl 27):28–46

27.

Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P (2018) Evaluation and management of youth-onset type 2 diabetes: a position statement by the American Diabetes Association. Diabetes Care 41(12):2648–2668. https://doi.org/10.2337/dci18-0052

28.

Klingensmith GJ, Pyle L, Arslanian S et al (2010) The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study. Diabetes Care 33(9):1970–1975. https://doi.org/10.2337/dc10-0373 CrossRefPubMedPubMedCentral

29.

Turner R, Stratton I, Horton V et al (1997) UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 350(9087):1288–1293. https://doi.org/10.1016/s0140-6736(97)03062-6 CrossRefPubMed

30.

Couper JJ, Haller MJ, Greenbaum CJ et al (2018) ISPAD Clinical Practice Consensus Guidelines 2018: stages of type 1 diabetes in children and adolescents. Pediatr Diabetes 19(Suppl 27):20–27CrossRefPubMed

31.

Ziegler AG, Rewers M, Simell O et al (2013) Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309(23):2473–2479. https://doi.org/10.1001/jama.2013.6285 CrossRefPubMedPubMedCentral

32.

Sosenko JM, Skyler JS, Palmer JP et al (2013) The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care 36(9):2615–2620. https://doi.org/10.2337/dc13-0425 CrossRefPubMedPubMedCentral

33.

The RISE Consortium (2018) Impact of insulin and metformin versus metformin alone on beta-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care 41: 1717–1725

34.

RISE Consortium (2018) Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: II. Observations using the oral glucose tolerance test. Diabetes Care 41:1707–1716CrossRef

35.

RISE Consortium (2018) Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: I. Observations using the hyperglycemic clamp. Diabetes Care 41:1696–1706CrossRef

36.

RISE Consortium (2019) Effects of treatment of impaired glucose tolerance or recently diagnosed type 2 diabetes with metformin alone or in combination with insulin glargine on β-cell function: comparison of responses in youth and adults. Diabetes 68:1670–1680CrossRef

37.

Bacha F, Gungor N, Lee S, Arslanian SA (2013) Progressive deterioration of beta-cell function in obese youth with type 2 diabetes. Pediatr Diabetes 14(2):106–111. https://doi.org/10.1111/j.1399-5448.2012.00915.x CrossRefPubMed

38.

D’Adamo E, Caprio S (2011) Type 2 diabetes in youth: epidemiology and pathophysiology. Diabetes Care 34(Suppl 2):S161–S165CrossRefPubMedPubMedCentral

39.

Druet C, Tubiana-Rufi N, Chevenne D, Rigal O, Polak M, Levy-Marchal C (2006) Characterization of insulin secretion and resistance in type 2 diabetes of adolescents. J Clin Endocrinol Metab 91(2):401–404. https://doi.org/10.1210/jc.2005-1672 CrossRefPubMed

40.

Zeitler P, Epstein L, Grey M et al (2007) Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes 8(2):74–87. https://doi.org/10.1111/j.1399-5448.2007.00237.x CrossRefPubMed

41.

Zeitler P, Hirst K, Pyle L et al (2012) A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 366(24):2247–2256. https://doi.org/10.1056/NEJMoa1109333 CrossRefPubMed

42.

Sànchez-Santos R, Sabench Pereferrer F, Estèvez Fernandez S et al (2013) Is the morbid obesity surgery profitable in times of crisis? A cost-benefit analysis of bariatric surgery. Cir Esp 91:476–484 [article in Spanish]CrossRefPubMed

43.

Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355(23):2427–2443. https://doi.org/10.1056/NEJMoa066224 CrossRefPubMed

44.

Kavey RE, Allada V, Daniels SR et al (2007) Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research. J Cardiovasc Nurs 22(3):218–253. https://doi.org/10.1097/01.JCN.0000267827.50320.85 CrossRefPubMed

45.

Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents (2011) Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 128(Suppl 5): S213-S256

46.

Dabelea D, Stafford JM, Mayer-Davis EJ et al (2017) Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. JAMA 317(8):825–835. https://doi.org/10.1001/jama.2017.0686 CrossRefPubMedPubMedCentral

47.

Hamman RF, Bell RA, Dabelea D et al (2014) The SEARCH for Diabetes in Youth study: rationale, findings, and future directions. Diabetes Care 37(12):3336–3344. https://doi.org/10.2337/dc14-0574 CrossRefPubMedPubMedCentral

48.

Snell-Bergeon JK, Nadeau K (2012) Cardiovascular disease risk in young people with type 1 diabetes. J Cardiovasc Transl Res 5:446–462CrossRefPubMed

49.

Nadeau KJ, Reusch JE (2011) Cardiovascular function/dysfunction in adolescents with type 1 diabetes. Curr Diab Rep 11:185–192CrossRefPubMed

50.

Bjornstad P, Truong U, Pyle L et al (2016) Youth with type 1 diabetes have worse strain and less pronounced sex differences in early echocardiographic markers of diabetic cardiomyopathy compared to their normoglycemic peers: a RESistance to InSulin in Type 1 ANd Type 2 diabetes (RESISTANT) Study. J Diabetes Complicat 30(6):1103–1110. https://doi.org/10.1016/j.jdiacomp.2016.04.008

51.

Bjornstad P, Snell-Bergeon JK, Nadeau KJ, Maahs DM (2015) Insulin sensitivity and complications in type 1 diabetes: new insights. World J Diabetes 6(1):8–16. https://doi.org/10.4239/wjd.v6.i1.8

52.

Bjornstad P, Cree-Green M, Baumgartner A et al (2015) Renal function is associated with peak exercise capacity in adolescents with type 1 diabetes. Diabetes Care 38(1):126–131. https://doi.org/10.2337/dc14-1742 CrossRefPubMed

53.

Cree-Green M, Bergman BC, Cengiz E et al (2019) Metformin improves peripheral insulin sensitivity in youth with type 1 diabetes. J Clin Endocrinol Metab 104:3265–3278CrossRefPubMedPubMedCentral

54.

Nadeau KJ, Zeitler PS, Bauer TA et al (2009) Insulin resistance in adolescents with type 2 diabetes is associated with impaired exercise capacity. J Clin Endocrinol Metab 94:3687–3695CrossRefPubMedPubMedCentral

55.

Shah AS, El Ghormli L, Gidding SS et al (2018) Prevalence of arterial stiffness in adolescents with type 2 diabetes in the TODAY cohort: relationships to glycemic control and other risk factors. J Diabetes Complicat 32:740–745

56.

Bjornstad P, Truong U, Dorosz JL et al (2016) Cardiopulmonary dysfunction and adiponectin in adolescents with type 2 diabetes. J Am Heart Assoc 5:e002804CrossRefPubMedPubMedCentral

57.

Bacha F, Gidding SS, Pyle L et al (2016) Relationship of cardiac structure and function to cardiorespiratory fitness and lean body mass in adolescents and young adults with type 2 diabetes. J Pediatr 177:159–166 e151CrossRefPubMedPubMedCentral

58.

Levitt Katz L, Gidding SS, Bacha F et al (2015) Alterations in left ventricular, left atrial, and right ventricular structure and function to cardiovascular risk factors in adolescents with type 2 diabetes participating in the TODAY clinical trial. Pediatr Diabetes 16(1):39–47. https://doi.org/10.1111/pedi.12119 CrossRefPubMed

59.

Shah AS, Khoury PR, Dolan LM et al (2011) The effects of obesity and type 2 diabetes mellitus on cardiac structure and function in adolescents and young adults. Diabetologia 54(4):722–730. https://doi.org/10.1007/s00125-010-1974-7 CrossRefPubMed

60.

Nadeau KJ, Klingensmith G, Zeitler P (2005) Type 2 diabetes in children is frequently associated with elevated alanine aminotransferase. J Pediatr Gastroenterol Nutr 41:94–98CrossRefPubMed

61.

Newton KP, Hou J, Crimmins NA et al (2016) Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease. JAMA Pediatr 170:e161971CrossRefPubMedPubMedCentral

62.

Dart AB, Martens PJ, Rigatto C, Brownell MD, Dean HJ, Sellers EA (2014) Earlier onset of complications in youth with type 2 diabetes. Diabetes Care 37(2):436–443. https://doi.org/10.2337/dc13-0954 CrossRefPubMed

63.

Tancredi M, Rosengren A, Svensson AM et al (2015) Excess mortality among persons with type 2 diabetes. N Engl J Med 373:1720–1732CrossRefPubMed

64.

Livingstone SJ, Levin D, Looker HC et al (2015) Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA 313(1):37–44. https://doi.org/10.1001/jama.2014.16425 CrossRefPubMedPubMedCentral

65.

Rawshani A, Rawshani A, Franzen S et al (2017) Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 376(15):1407–1418. https://doi.org/10.1056/NEJMoa1608664 CrossRefPubMed

66.

Wood JR, Miller KM, Maahs DM et al (2013) Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care 36(7):2035–2037. https://doi.org/10.2337/dc12-1959 CrossRefPubMedPubMedCentral

67.

Nathan DM, Genuth S, Lachin J et al (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329(14):977–986. https://doi.org/10.1056/NEJM199309303291401 CrossRefPubMed

68.

Barr CC (2001) Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive insulin therapy, by The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N. Engl. J. Med 342:381-9, 2000. Surv Ophthalmol 45: 459–460, 5, https://doi.org/10.1016/s0039-6257(01)00187-4

69.

UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:854–865CrossRef

70.

Chan CL, Pyle L, Morehead R, Baumgartner A, Cree-Green M, Nadeau KJ (2017) The role of glycemia in insulin resistance in youth with type 1 and type 2 diabetes. Pediatr Diabetes 18(6):470–477. https://doi.org/10.1111/pedi.12422 CrossRefPubMed

71.

DiMeglio LA, Acerini CL, Codner E et al (2018) ISPAD Clinical Practice Consensus Guidelines 2018: glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes 19(Suppl 27):105–114

72.

Rege NK, Phillips NFB, Weiss MA (2017) Development of glucose-responsive ‘smart’ insulin systems. Curr Opin Endocrinol Diabetes Obes 24:267–278

73.

Geho WB, Geho HC, Lau JR, Gana TJ (2009) Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation. J Diabetes Sci Technol 3(6):1451–1459. https://doi.org/10.1177/193229680900300627 CrossRefPubMedPubMedCentral

74.

Rodbard D (2017) Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes. Diabetes Technol Ther 19(S3):S25–S37. https://doi.org/10.1089/dia.2017.0035 CrossRefPubMed

75.

De Ridder F, den Brinker M, De Block C (2019) The road from intermittently scanned glucose monitoring to hybrid closed-loop systems: Part A. Keys to success: subject profiles, choice of systems, education. Ther Adv Endocrinol Metab 10:2042018819865399PubMedPubMedCentral

76.

Weaver KW, Hirsch IB (2018) The hybrid closed-loop system: evolution and practical applications. Diabetes Technol Ther 20(S2):S216–S223. https://doi.org/10.1089/dia.2018.0091 CrossRefPubMed

77.

Meng H, Zhang A, Liang Y, Hao J, Zhang X, Lu J (2018) Effect of metformin on glycaemic control in patients with type 1 diabetes: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev 34:e2983

78.

Libman IM, Miller KM, DiMeglio LA et al (2015) Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a Randomized Clinical Trial. JAMA 314:2241–2250

79.

Bjornstad P, Schafer M, Truong U et al (2018) Metformin improves insulin sensitivity and vascular health in youth with type 1 diabetes mellitus. Circulation 138(25):2895–2907. https://doi.org/10.1161/CIRCULATIONAHA.118.035525

80.

Riddle MC, Nahra R, Han J et al (2018) Control of postprandial hyperglycemia in type 1 diabetes by 24-hour fixed-dose coadministration of pramlintide and regular human insulin: a randomized, two-way crossover study. Diabetes Care 41(11):2346–2352. https://doi.org/10.2337/dc18-1091 CrossRefPubMed

81.

Qiao YC, Ling W, Pan YH et al (2017) Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis. Oncotarget 8(39):66504–66515. https://doi.org/10.18632/oncotarget.16008 CrossRefPubMedPubMedCentral

82.

Janzen KM, Steuber TD, Nisly SA (2016) GLP-1 agonists in type 1 diabetes mellitus. Ann Pharmacother 50(8):656–665. https://doi.org/10.1177/1060028016651279 CrossRefPubMed

83.

McCrimmon RJ, Henry RR (2018) SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia 61:2126–2133CrossRefPubMedPubMedCentral

84.

Vaarala O, Ilonen J, Ruohtula T et al (2012) Removal of bovine insulin from cow’s milk formula and early initiation of beta-cell autoimmunity in the FINDIA pilot study. Arch Pediatr Adolesc Med 166(7):608–614. https://doi.org/10.1001/archpediatrics.2011.1559 CrossRefPubMed

85.

Hummel S, Pfluger M, Hummel M, Bonifacio E, Ziegler AG (2011) Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care 34:1301–1305CrossRefPubMedPubMedCentral

86.

Goodwin G (2019) Type 1 diabetes mellitus and celiac disease: distinct autoimmune disorders that share common pathogenic mechanisms. Horm Res Paediatr:1–8. https://doi.org/10.1159/000503142

87.

Yu H, Paiva R, Flavell RA (2018) Harnessing the power of regulatory T-cells to control autoimmune diabetes: overview and perspective. Immunology 153(2):161–170. https://doi.org/10.1111/imm.12867 CrossRefPubMed

88.

Haller MJ, Long SA, Blanchfield JL et al (2019) Low-dose anti-thymocyte globulin preserves c-peptide, reduces HbA_1c, and increases regulatory to conventional T-cell ratios in new-onset type 1 diabetes: two-year clinical trial data. Diabetes 68(6):1267–1276. https://doi.org/10.2337/db19-0057 CrossRefPubMedPubMedCentral

89.

Herold KC, Bundy BN, Long SA et al (2019) An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 381(7):603–613. https://doi.org/10.1056/NEJMoa1902226

90.

Willi SM, Martin K, Datko FM, Brant BP (2004) Treatment of type 2 diabetes in childhood using a very-low-calorie diet. Diabetes Care 27(2):348–353. https://doi.org/10.2337/diacare.27.2.348 CrossRefPubMed

91.

Wittmeier KD, Wicklow BA, Sellers EA, Griffith AT, Dean HJ, McGavock JM (2012) Success with lifestyle monotherapy in youth with new-onset type 2 diabetes. Paediatr Child Health 17:129–132CrossRefPubMedPubMedCentral

92.

Burns N, Finucane FM, Hatunic M et al (2007) Early-onset type 2 diabetes in obese white subjects is characterised by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training. Diabetologia 50(7):1500–1508. https://doi.org/10.1007/s00125-007-0655-7 CrossRefPubMed

93.

Zeitler P, Fu J, Tandon N et al (2014) ISPAD Clinical Practice Consensus Guidelines 2014. Type 2 diabetes in the child and adolescent. Pediatr Diabetes 15(Suppl 20):26–46CrossRefPubMed

94.

Han E, Shin E, Kim G et al (2018) Combining SGLT2 inhibition with a thiazolidinedione additively attenuate the very early phase of diabetic nephropathy progression in type 2 diabetes mellitus. Front Endocrinol 9:412CrossRef

95.

Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311–322. https://doi.org/10.1056/NEJMoa1603827 CrossRefPubMedPubMedCentral

96.

Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720 CrossRefPubMed

97.

Klein DJ, Battelino T, Chatterjee DJ, Jacobsen LV, Hale PM, Arslanian S (2014) Liraglutide’s safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Technol Ther 16(10):679–687. https://doi.org/10.1089/dia.2013.0366 CrossRefPubMedPubMedCentral

98.

de Wit HM, Te Groen M, Rovers MM, Tack CJ (2016) The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis. Br J Clin Pharmacol 82:301–314CrossRefPubMedPubMedCentral

99.

Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644–657. https://doi.org/10.1056/NEJMoa1611925

100.

Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323–334. https://doi.org/10.1056/NEJMoa1515920 CrossRefPubMed

101.

Rubino F, Nathan DM, Eckel RH et al (2016) Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Surg Obes Relat Dis 12(6):1144–1162. https://doi.org/10.1016/j.soard.2016.05.018

102.

Pratt JS, Lenders CM, Dionne EA et al (2009) Best practice updates for pediatric/adolescent weight loss surgery. Obesity 17:901–910CrossRefPubMed

103.

Inge TH, Courcoulas AP, Jenkins TM et al (2016) Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med 374(2):113–123. https://doi.org/10.1056/NEJMoa1506699 CrossRefPubMed

104.

Inge TH, Miyano G, Bean J et al (2009) Reversal of type 2 diabetes mellitus and improvements in cardiovascular risk factors after surgical weight loss in adolescents. Pediatrics 123(1):214–222. https://doi.org/10.1542/peds.2008-0522 CrossRefPubMed

105.

Inge TH, Courcoulas AP, Jenkins TM et al (2019) Five-year outcomes of gastric bypass in adolescents as compared with adults. N Engl J Med 380(22):2136–2145. https://doi.org/10.1056/NEJMoa1813909 CrossRefPubMedPubMedCentral

106.

Inge TH, Laffel LM, Jenkins TM et al (2018) Comparison of surgical and medical therapy for type 2 diabetes in severely obese adolescents. JAMA Pediatr 172:452–460CrossRefPubMedPubMedCentral

107.

Inge TH, Coley RY, Bazzano LA et al (2018) Comparative effectiveness of bariatric procedures among adolescents: the PCORnet bariatric study. Surg Obes Relat Dis 14(9):1374–1386. https://doi.org/10.1016/j.soard.2018.04.002

108.

Chuang J, Zeller MH, Inge T, Crimmins N (2013) Bariatric surgery for severe obesity in two adolescents with type 1 diabetes. Pediatrics 132:e1031–e1034CrossRefPubMedPubMedCentral

Titel: The changing face of paediatric diabetes
verfasst von: Amy S. Shah
Kristen J. Nadeau
Publikationsdatum: 02.01.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 4/2020
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-019-05075-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The changing face of paediatric diabetes

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Secular trends in all-cause and cause-specific mortality rates in people with diabetes in Hong Kong, 2001–2016: a retrospective cohort study

How conclusive is the CONCLUDE trial?

Neuronal control of peripheral nutrient partitioning

Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial

Red meat, poultry and fish consumption and risk of diabetes: a 9 year prospective cohort study of the China Kadoorie Biobank

Pregnancy in teenagers diagnosed with type 1 diabetes mellitus in childhood: a national population-based e-cohort study

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin